SEC Form 4/A · accession 0001437749-26-029235
Monopar Therapeutics · MNPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Kim R Tsuchimoto
Director
Period of report
Aug 26, 2026
Accepted (ET)
Aug 28, 2026 · 8:18 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001645469
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 26, 2026 | M | 2,055 | $30.00 | A | 2,055 | D | |
| Common Stock | Aug 26, 2026 | M | 2,035 | $14.00 | A | 4,090 | D | |
| Common StockF4 | Aug 26, 2026 | S | 485 | $108.83 | D | 3,605 | D | |
| Common StockF5 | Aug 26, 2026 | S | 615 | $109.56 | D | 2,990 | D | |
| Common StockF6 | Aug 26, 2026 | S | 700 | $110.65 | D | 2,290 | D | |
| Common StockF7 | Aug 26, 2026 | S | 1,098 | $111.84 | D | 1,192 | D | |
| Common StockF8 | Aug 26, 2026 | S | 602 | $112.93 | D | 590 | D | |
| Common StockF9 | Aug 26, 2026 | S | 590 | $113.84 | D | 0 | D | |
| Common StockF10 | holding | — | — | — | 11,486 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2 | $30.00 | Aug 26, 2026 | M | 2,055 | A | — | Aug 27, 2028 | Common Stock | 2,055 | 6,165 | D |
| Stock OptionF3 | $14.00 | Aug 26, 2026 | M | 2,035 | A | — | Jun 30, 2029 | Common Stock | 2,035 | 8,140 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
- F10Represents shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015.
- F2On August 28, 2018, the reporting person was granted stock options to purchase up to 8,220 shares of common stock. The options vest 6/51 on the six-month anniversary of vesting commencement date of October 1, 2018 and 1/51 per month thereafter.
- F3On February 2, 2022, the reporting person was granted stock options to purchase up to 16,279 shares of common stock. The options vest 6/48ths on June 30, 2022 and 1/48ths per month thereafter.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.07 to $109.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.07 to $110.04, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.14 to $111.05, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
- F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.30 to $112.27, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
- F8The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.30 to $113.25, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
- F9The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.35 to $114.34, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (4) through (9) to this Form 4.
Remarks
On August 27, 2026, the reporting person filed a Form 4, which inadvertently omitted two option exercises that were made prior to the reporting person's sale of shares of common stock. Both the option exercises and the sales of common stock were effected pursuant to a Rule 10b5-1 Plan.